Breakpoint Therapeutics

Breakpoint Therapeutics Announces Development Candidate Nomination and Start of IND-Enabling Activities of Potential Best-in-Class Polymerase Theta (Pol θ / POLQ) Inhibitor - Breakpoint’s polymerase theta inhibitor development candidate, a potent and selective small molecule, was nominated based on its best-in-class potential to treat cancers with defined defects in DDR pathways - Excellent profile of Breakpoint’s polymerase theta inhibitor provides mechanistic synergy and huge optionality for clinical combination with various other agents, including targeted drugs such as PARP inhibitors, chemo- and radiation therapy, radioligand therapy (RLT) and ADCs - Candidate molecule originated from integrated drug discovery efforts performed in alliance with Evotec See the press release here: https://lnkd.in/eqDqx6cn

I am pleased to be representing Breakpoint Therapeutics at #ESMOTAT24 which has just kicked off in Paris. The agenda is packed full of #precisiononcology enabling technologies and strategies: #ctdna, actionable genetic variants, surrogate endpoints, dosage and combination dosage optimisation and so much more! Very much looking forward to learning more about progress at the cutting edge of early #clinicaltrial design in #oncology. Want to meet and hear about our programmes? Feel free to reach out by DM

This weekend I will be heading to San Francisco where nearly all companies of our industry come together to attend the J.P. Morgan Healthcare Conference and/or one of the many satellite events during #JPM2024. As always, #jpm promises to be fantastic to make new connections and catch up with peers, partners and investors. I will also present a company overview of Breakpoint Therapeutics GmbH at Biotech Showcase on January 9, 2024 and highlight exciting progress that we’ve made in our drug discovery research. See you there! 

ANNOUNCEMENT: Incubate Bio and Breakpoint Therapeutics GmbH announce collaboration to accelerate DNA Damage Response (DDR) drug discovery. - Breakpoint applying Incubate Bio’s AI technologies to advance in-house programmes – Incubate Bio (IBI) and Breakpoint Therapeutics announce a collaboration to utilize the ALaSCA software platform to advance Breakpoint’s portfolio of DNA Damage Response (DDR) related targets. “The ability to gain additional pathway insights holds great promise,” commented Daniel Speidel, Managing Director, Breakpoint Therapeutics. “Working with the multi-disciplinary team at IBI will help us to quickly receive rich interrogatable datasets, enabling us to further execute on our strategy to address this challenging area of biology.” Alterations in DDR pathways are prominent in many cancers. Targeting various DDR proteins with novel drugs is therefore an attractive strategy to help patients with difficult-to-treat disease. Considerable amounts of research and data have been generated in and around this burgeoning area of interest, making navigation and assessment of the mass of information available a complex challenge. As an AI- based tool, ALaSCA is ideally suited to supporting researchers in this time consuming and laborious work, without institutional or scientific bias. For more about ALaSCA: https://lnkd.in/em__x-ci Incubate Bio Breakpoint Therapeutics GmbH Jon Hollick Francois Aymard Riaan Conradie Zachariah George Tony Sedgwick William Hicks Lynne Trowbridge Radouane Oudrhiri James FRY Neil Wilkie Sunil Shah SLAS (Society for Laboratory Automation and Screening) Mostafa Analoui

https://lnkd.in/evft2zNS

Breakpoint Therapeutics is in London for Jefferies European Life Science Investment week! Meet our Managing Directors Jon Hollick and Daniel Speidel at the 8th LSX #Investival Showcase on Monday November 13, or amongst the 650 public & private healthcare companies, institutional and private equity investors at the #JefferiesHealthcare Conference on November 14-16. We look forward to making and renewing connections with peers, partners and potential investors. #biotech #oncology #ddr #venturecapital